Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Recommendation of "Hold" from Brokerages

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) has earned an average recommendation of "Hold" from the five brokerages that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $13.75.

A number of brokerages recently issued reports on TBPH. Leerink Partners cut shares of Theravance Biopharma from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $15.00 to $10.00 in a research report on Tuesday, August 6th. StockNews.com cut Theravance Biopharma from a "buy" rating to a "hold" rating in a research report on Saturday, August 10th. Leerink Partnrs lowered Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 6th. TD Cowen dropped their target price on Theravance Biopharma from $10.00 to $9.00 and set a "hold" rating on the stock in a report on Tuesday, August 6th. Finally, HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Theravance Biopharma in a report on Monday, September 16th.

Theravance Biopharma Trading Up 2.1 %

Shares of TBPH stock traded up $0.18 during midday trading on Friday, reaching $8.80. 102,008 shares of the stock were exchanged, compared to its average volume of 362,683. The firm has a market cap of $427.97 million, a PE ratio of -10.23 and a beta of 0.25. The company's 50 day moving average is $8.18 and its two-hundred day moving average is $8.77. Theravance Biopharma has a 1 year low of $7.44 and a 1 year high of $11.71.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last issued its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.25). Theravance Biopharma had a negative return on equity of 21.29% and a negative net margin of 73.61%. The firm had revenue of $14.26 million during the quarter, compared to analysts' expectations of $15.81 million. During the same period in the previous year, the company earned ($0.28) earnings per share. As a group, equities analysts expect that Theravance Biopharma will post -1.04 EPS for the current fiscal year.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, major shareholder Eli Samaha purchased 999,800 shares of the firm's stock in a transaction dated Wednesday, August 7th. The stock was purchased at an average price of $7.80 per share, for a total transaction of $7,798,440.00. Following the completion of the purchase, the insider now directly owns 9,511,150 shares of the company's stock, valued at $74,186,970. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 6.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. Jacobs Levy Equity Management Inc. increased its position in Theravance Biopharma by 41.6% during the first quarter. Jacobs Levy Equity Management Inc. now owns 557,971 shares of the biopharmaceutical company's stock valued at $5,005,000 after acquiring an additional 163,951 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Theravance Biopharma by 38.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 330,181 shares of the biopharmaceutical company's stock valued at $2,800,000 after purchasing an additional 91,679 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Theravance Biopharma by 83.6% in the 2nd quarter. Marshall Wace LLP now owns 297,499 shares of the biopharmaceutical company's stock worth $2,523,000 after purchasing an additional 135,426 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Theravance Biopharma by 68.0% in the fourth quarter. Wellington Management Group LLP now owns 287,102 shares of the biopharmaceutical company's stock worth $3,227,000 after buying an additional 116,164 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Theravance Biopharma by 6.3% in the first quarter. SG Americas Securities LLC now owns 209,566 shares of the biopharmaceutical company's stock worth $1,880,000 after buying an additional 12,460 shares during the last quarter. 99.10% of the stock is owned by hedge funds and other institutional investors.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.